PRLD

Peers: DMRA INCY OLMA PTGX GERN ARVN CCCC KPTI KYMR PFE

| Held by: VTI IWM VXF IWO VTWO IWC BUSM VTWG AVSC DFAS

Index	RUT
Market Cap	306.45M
Enterprise Value	172.34M
Income	-60.49M
Sales	22.42M
Book/sh	1.68
Cash/sh	1.90
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	79
IPO	Sep 25, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	13.67
P/B	2.29
P/C	2.02
P/FCF	-
EV/EBITDA	-
EV/Sales	7.69
Quick Ratio	4.07
Current Ratio	4.07
Debt/Eq	0.13
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	-0.79
EPS next Y	-0.48
EPS next Q	0.01
EPS this Y	68.84%
EPS next Y	-18.41%
EPS next 5Y	57.36%
EPS past 3/5Y	19.05% 0.15%
Sales past 3/5Y	- -
EPS Y/Y TTM	55.73%
Sales Y/Y TTM	220.34%
EPS Q/Q	65.57%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	28.83% -

Insider Own	43.95%
Insider Trans	0.00%
Inst Own	44.95%
Inst Trans	18.00%
ROA	-39.76%
ROE	-57.73%
ROIC	-40.70%
Gross Margin	92.92%
Oper. Margin	-300.56%
Profit Margin	-269.75%
SMA20	3.98%
SMA50	-12.70%
SMA200	-4.48%
Trades

Shs Outstand	65.03M
Shs Float	44.73M
Short Float	11.40%
Short Ratio	10.42
Short Interest	5.10M
52W High	6.83 -43.78%
52W Low	1.17 227.37%
Volatility	8.58% 7.77%
ATR (14)	0.30
RSI (14)	47.99
Beta	1.19
Rel Volume	0.00
Avg Volume	489.41K
Volume	0

Perf Week	3.78%
Perf Month	4.63%
Perf Quarter	-15.04%
Perf Half Y	-18.99%
Perf YTD	32.41%
Perf Year	141.51%
Perf 3Y	73.76%
Perf 5Y	-79.05%
Perf 10Y	-
Recom	1.00
Target Price	9.20
Prev Close	3.84
Price	3.84
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$9.20

Implied Upside

+139.6%

Analysts9incl. previous ratings

Rating Distribution5 Buy · 1 Hold · 3 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 17, 2026	Initiated	JJP Morgan	Overweight	$12	+212.5%
May 04, 2026	Initiated	DD. Boral Capital	Buy	$9	+134.4%
Sep 19, 2024	Upgrade	HH.C. Wainwright	Neutral → Buy	$5	+30.2%
Jun 20, 2024	Downgrade	BBarclays	Equal Weight → Underweight	$3	-21.9%
Mar 13, 2024	Initiated	JJMP Securities	Mkt Outperform	$7	+82.3%
Feb 20, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral	$5	+30.2%
Dec 19, 2023	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$10 → $4	+4.2%
Nov 21, 2022	Downgrade	BBofA Securities	Neutral → Underperform	$8 → $6	+56.3%
Sep 09, 2022	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$19 → $11	+186.5%
Jul 29, 2022	Initiated	JJefferies	Buy	$9	+134.4%
Mar 15, 2022	Downgrade	BBofA Securities	Buy → Neutral	$50 → $10	+160.4%
Feb 28, 2022	Downgrade	BBarclays	Overweight → Equal Weight	$20 → $12	+212.5%
Oct 08, 2021	Upgrade	MMorgan Stanley	Equal-Weight → Overweight
Jul 27, 2021	Upgrade	BBofA Securities	Neutral → Buy	$60	+1,462.5%
Apr 26, 2021	Initiated	HH.C. Wainwright	Buy	$62	+1,514.6%
Mar 09, 2021	Initiated	BBarclays	Overweight	$80	+1,983.3%
Nov 20, 2020	Downgrade	BBofA Securities	Buy → Neutral	$40 → $60	+1,462.5%
Oct 20, 2020	Initiated	MMorgan Stanley	Equal-Weight	$34	+785.4%
Oct 20, 2020	Initiated	GGoldman	Neutral	$37	+863.5%
Oct 20, 2020	Initiated	BBofA Securities	Buy	$40	+941.7%

Oct-16-26 04:01PM	Prelude Therapeutics to Participate in the Chardan Healthcare Conference (GlobeNewswire)
Oct-13-26 01:11PM	Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial (Stocktwits)
07:01AM	Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio and Inluriyo in Patients with HR+/HER2- Breast Cancer (GlobeNewswire)
Sep-11-26 07:01AM	Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Sep-10-26 07:01AM	Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader (GlobeNewswire) -8.25%
12:07PM	Loading…
Aug-12-26 12:07PM	Sellas Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global Analyst Sees About 200% Upside Potential (Stocktwits) +7.71%
Aug-11-26 07:00AM	Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +10.14%
May-12-26 07:01AM	Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-20-26 06:30AM	Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering (GlobeNewswire)
06:00AM	Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
Apr-15-26 07:30AM	Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer (GlobeNewswire) +25.45%
Mar-17-26 04:31PM	Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting (GlobeNewswire) -9.04%
Mar-11-26 05:15AM	Prelude Therapeutics price target raised to $6 from $3 at Citizens (TipRanks) +5.83%
Mar-10-26 07:01AM	Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 (GlobeNewswire) +16.50%
Feb-03-26 09:00AM	Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor (GlobeNewswire) +12.81%
11:00AM	Loading…
Dec-06-25 11:00AM	Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs (GlobeNewswire)
Nov-24-25 08:10AM	Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus (Zacks) -16.17%
Nov-12-25 04:01PM	Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com) +8.89%
07:01AM	Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 07:05AM	Prelude Therapeutics Announces Strategic Business Update (GlobeNewswire) -55.78%
07:01AM	Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors (GlobeNewswire)
Nov-03-25 09:01AM	Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting (GlobeNewswire) +150.31%
Oct-17-25 07:30AM	Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors (GlobeNewswire) -9.16%
Aug-14-25 07:00AM	Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-02-25 07:30AM	Prelude Therapeutics to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
May-06-25 04:05PM	Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-25 07:30AM	Prelude Therapeutics to Participate in Citizens Life Sciences Conference (GlobeNewswire)
Apr-25-25 04:05PM	Prelude Announces Presentations at 2025 AACR Annual Meeting (GlobeNewswire)
Apr-10-25 12:00PM	Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-10-25 07:30AM	Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 (GlobeNewswire) -8.97%
07:30AM	Loading…
Mar-05-25 07:30AM	Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference (GlobeNewswire)
Dec-12-24 07:35AM	Prelude Therapeutics presents first interim data from trial of PRT2527 (TipRanks) -5.83%
Dec-11-24 07:30AM	Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies (GlobeNewswire)
Nov-27-24 09:35AM	After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD) (Zacks) +7.14%
07:30AM	Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-11-24 09:35AM	Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) (Zacks)
Nov-06-24 04:05PM	Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-27-24 01:15PM	Prelude Therapeutics price target lowered to $1 from $3 at Barclays (TipRanks)
Oct-24-24 07:30AM	Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium (GlobeNewswire) -5.49%
Oct-09-24 07:30AM	Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium (GlobeNewswire) -6.86%
Sep-13-24 10:00AM	Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial (GlobeNewswire) -42.65%
Sep-09-24 07:30AM	Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-29-24 09:33AM	MSD discontinues two Phase III Keytruda trials (Clinical Trials Arena)
Aug-12-24 07:01AM	Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.86%
Jul-10-24 06:53AM	Prelude and MSD partner to trial PRT3789 and Keytruda combination (Clinical Trials Arena)
Jul-09-24 07:30AM	Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA (pembrolizumab) in Patients with SMARCA4-Mutated Cancers (GlobeNewswire)
Jun-20-24 09:54AM	Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls (The Fly)
Jun-03-24 07:01AM	Prelude Therapeutics to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
May-09-24 07:01AM	Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference (GlobeNewswire) +13.37%
May-07-24 01:53PM	PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
07:01AM	Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-09-24 04:35PM	Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting (GlobeNewswire) +6.17%
Mar-05-24 04:45PM	Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting (GlobeNewswire)
Feb-29-24 04:05PM	Prelude Therapeutics to Participate in Barclays Global Healthcare Conference (GlobeNewswire) +6.74%
Feb-15-24 04:05PM	Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 (GlobeNewswire) +33.05%
Dec-11-23 09:34AM	Prelude Therapeutics Announces $25 Million Private Placement (GlobeNewswire)
Nov-03-23 08:42AM	Q3 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
05:55AM	Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress (GuruFocus.com)
Nov-01-23 04:10PM	Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results (GlobeNewswire) +10.06% +18.82%
04:05PM	Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology (GlobeNewswire)
Oct-14-23 12:30PM	Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference (GlobeNewswire)
Oct-04-23 12:00PM	All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy (Zacks)
Aug-29-23 08:30AM	Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-03-23 08:00AM	Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-10-23 08:13AM	We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-02-23 11:36AM	Insider Buying Alert: These 10 Stocks are Seeing Significant Insider Activity (Insider Monkey)
May-31-23 08:30AM	Prelude Therapeutics To Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-28-23 08:11AM	Krishna Vaddi Buys Handful Of Shares In Prelude Therapeutics \ (Simply Wall St.)
May-18-23 07:00AM	Prelude Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -11.43%
May-17-23 04:08PM	Prelude Therapeutics Announces Launch of Proposed Public Offering (GlobeNewswire)
May-08-23 08:30AM	Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update (GlobeNewswire)
Apr-27-23 08:30AM	Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May (GlobeNewswire)
Apr-11-23 08:30AM	Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference (GlobeNewswire) +9.01%
Apr-07-23 09:34AM	Prelude Therapeutics Incorporated (NASDAQ:PRLD) most popular amongst private equity firms who own 33% of the shares, institutions hold 24% (Simply Wall St.)
Mar-18-23 06:48PM	The 7 Worst Stocks to Buy Now (InvestorPlace)
Mar-16-23 12:06PM	Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate (Zacks)
Mar-15-23 08:30AM	Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.49%
08:00AM	Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers (GlobeNewswire)
Mar-01-23 08:30AM	Prelude Therapeutics To Participate in Barclays Global Healthcare Conference (GlobeNewswire)
Feb-09-23 09:05AM	Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire)
Jan-30-23 09:38AM	We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate (Simply Wall St.) -5.45%
Dec-24-22 07:05AM	Krishna Vaddi Is The Founder of Prelude Therapeutics Incorporated (NASDAQ:PRLD) And Just Spent US$98k On Shares (Simply Wall St.)
Nov-25-22 08:06AM	Prelude Therapeutics Incorporated (NASDAQ:PRLD) drops to US$317m and insiders who purchased earlier this year lose another US$17k (Simply Wall St.)
Nov-14-22 08:00AM	Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -8.82%
Oct-18-22 08:00AM	Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader (GlobeNewswire)
Sep-06-22 08:00AM	Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences (GlobeNewswire) -5.48%
Aug-23-22 06:39AM	Prelude Therapeutics (NASDAQ:PRLD) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-10-22 09:25AM	Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season? (Zacks) +22.43%
Aug-09-22 08:00AM	Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Jul-05-22 09:22PM	'I wanted to build it here': Life sciences startup leaders talk about challenges of growing in Philadelphia (American City Business Journals) +7.18%
Jun-22-22 09:55AM	Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know (Zacks)
May-25-22 06:35AM	Prelude Therapeutics Incorporated (NASDAQ:PRLD) drops to US$206m and insiders who purchased earlier this year lose another US$60k (Simply Wall St.)
May-10-22 08:00AM	Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update (GlobeNewswire) +9.50%
Mar-16-22 07:30AM	Prelude Therapeutics Reports Full Year 2021 Financial Results (GlobeNewswire) +8.39%
06:39AM	Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-11-22 08:00AM	Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference (GlobeNewswire)
Mar-09-22 08:05AM	Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting (GlobeNewswire) +7.53%
08:00AM	Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer (GlobeNewswire)
Feb-11-22 07:00AM	Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bonita David P	Director	Apr 21 '26	Buy	4.44	2,815,315	12,499,999	11,808,945	Apr 23 06:50 PM
ORBIMED ADVISORS LLC	Director	Apr 21 '26	Buy	4.44	2,815,315	12,499,999	11,808,945	Apr 23 06:48 PM

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Ph.D.Dr. Krishna Vaddi D.V.M.

CFOMr. Bryant David Lim J.D.

Chief Scientific OfficerDr. Peggy A. Scherle Ph.D.

Senior VP and Head of Strategic Planning & OperationsMs. Aimee Crombie Ph.D.

Senior Vice President of Technical OperationsDr. Madhu Pudipeddi Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Prelude Therapeutics Inc

Upgrade your Finviz experience